In combination with the much more effective treatment with BYL-719 compared to idelalisib, our data indicate that the resistance might also here be based on the higher level of p110α expression compared to p110δ in MCC cell lines. The gene discussed is PIK3CD; the disease is Merkel cell skin cancer.